Peter Marks, erstwhile manager of the halfway for biologics valuation and probe astatine the U.S. Food and Drug Administration (FDA), speaks during a Senate Health, Education, Labor, and Pensions Committee proceeding successful Washington, D.C., U.S., connected Tuesday, May 11, 2021.
Jim Lo Scalzo/EPA/Bloomberg via Getty Images